[Market Feature] HEM Pharma Hits Record High on News of Leading Production in Amway's New Project

HEM Pharma is showing strong performance in early trading.

As of 9:03 a.m. on December 2, HEM Pharma was trading at 53,600 won, up 8.28% (4,100 won) from the previous day. At one point, it rose to 54,500 won, marking a new 52-week high.

Investor sentiment has been boosted by news that the company will lead production in a new probiotics development project spearheaded by Amway's Nutrilite brand. This project is a new global product that maximizes gut health benefits by combining HEM Pharma's newly developed strains with plant-derived ingredients from Amway's farms.

HEM Pharma has completed all technical verification procedures between Korea and the United States, including an on-site inspection of its Sejong plant and a review of test reports, in collaboration with Amway's global headquarters. Having secured technical feasibility and supply chain reliability at the pilot stage, the company expects to accelerate its global market expansion going forward.

This content was produced with the assistance of AI translation services.